In the South and Central America pharmaceutical industry, there were 8 M&A deals announced in Q2 2023, worth a total value of $349.7m, according to GlobalData’s Deals Database. The $242.3m minority acquisition of hypera by votorantim was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in South and Central America decreased by 2% in Q2 2023 compared with the previous quarter’s total of $356.9m and fell by 29% as compared to Q2 2022. Related deal volume decreased by 27% in Q2 2023 versus the previous quarter and was 14% higher than in Q2 2022.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.